1. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
   J. Ettl et al, 2018, Annals of Oncology CrossRef
2. Platinum-containing regimens for triple-negative metastatic breast cancer
   null null et al, 2020, Cochrane Database of Systematic Reviews CrossRef
3. Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B16 bearing mice
   Nannan Lu et al, 2016, Drug Delivery CrossRef
4. Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer
   Jihui Chen et al, 2021, Cancer Cell International CrossRef
5. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
   S.A. Hurvitz et al, 2018, European Journal of Cancer CrossRef
6. Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review
   Zhibo Xie et al, 2018, Oncotarget CrossRef
7. Platinum-containing regimens for metastatic breast cancer
   Sam J Egger et al, 2017, Cochrane Database of Systematic Reviews CrossRef
8. Gemcitabine and Vinorelbine (GemVin) Regimen
   Elizabeth Y. Shang et al, 2014, Hospital Pharmacy CrossRef
9. Potential role of pemetrexed in metastatic breast cancer patients pre‐treated with anthracycline or taxane
   Li‐Yan Zhou et al, 2015, Chronic Diseases and Translational Medicine CrossRef
10. Pemetrexed ameliorates Con A-induced hepatic injury by restricting M1 macrophage activation
    Zhaiyi Liu et al, 2023, International Immunopharmacology CrossRef